share_log

NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA

NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA

NexgenRX 公佈了 2022 年年終業績,收入持續增長,息稅折舊攤銷前利潤爲正
Accesswire ·  2023/04/07 08:20

TORONTO, ON / ACCESSWIRE / April 6, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2022, once again highlighted by continued revenue growth and positive EBIDTA. The Company showed revenue growth of $939,942 in 2022 or 7.94% over the prior year, with a positive EBITDA of $1,626,524. The Company's cash position remained strong at $1,766,891, after total cash dividend payouts of $703,358 to the common shareholders.

安大略省多倫多/ACCESSWIRE/2023 年 4 月 6 日/NEXGENRX INC. (“NexgenRX” 或 “公司”)很高興地宣佈其截至2022年12月31日的財政年度的年度財務業績,持續的收入增長和積極的息稅折舊攤銷前利潤再次凸顯了這一點。該公司在2022年顯示收入增長939,942美元,比上年增長7.94%,息稅折舊攤銷前利潤爲1,626,524美元。在向普通股股東支付的現金股息總額爲703,358美元之後,該公司的現金狀況保持強勁,爲1,766,891美元。

Although the Company had numerous challenges throughout 2022, each challenge presented new opportunities and potential for the Company. Some of the Company's success stories included renewing its contract with one of its top five clients, expanding its SaaS (Software as a Service) offering to a wider range of customers and rewarding its shareholders with two dividend distributions. In addition, the Company officially transformed to a hybrid workplace model upon completion of its office move, which allows it to free up cash for other purposes. With various investments that the Company made upfront to develop and maintain customer relationships, together with distribution of dividends, a strong statement has been made that reflects the Company's capability of generating free cash flow.

儘管公司在整個 2022 年遇到了許多挑戰,但每項挑戰都爲公司帶來了新的機遇和潛力。該公司的一些成功案例包括續訂與前五大客戶之一的合同,將其SaaS(軟件即服務)產品擴展到更廣泛的客戶,以及通過兩次股息分配來獎勵股東。此外,公司在辦公室搬遷完成後正式向混合工作場所模式轉型,這使其能夠騰出現金用於其他用途。公司爲發展和維護客戶關係而預先進行了各種投資,並分配了股息,已經發表了一份強有力的聲明,反映了公司產生自由現金流的能力。

Ron Loucks, President and CEO, stated "I am proud of what we have accomplished in 2022 and look forward to what 2023 has to offer. We have a strong pipeline of activity in various segments of our business that we are systematically converting into successful revenue-generating opportunities. This year, we are entering a new phase as a technology solution provider, promoting and expanding our fully managed SaaS solutions that empowers our customers to self-manage their benefit plans effectively and efficiently." Mr. Loucks continued, "2023 marks the 20th anniversary of the incorporation of NexgenRx. This significant milestone is particularly gratifying to me as the Company continues to expand its reach in the marketplace with new and innovative product solutions."

總裁兼首席執行官羅恩·洛克斯表示:“我爲我們在 2022 年取得的成就感到自豪,並期待 2023 年所能提供的一切。我們在業務的各個領域都有強大的活動渠道,我們正在系統地將其轉化爲成功的創收機會。今年,作爲技術解決方案提供商,我們將進入一個新階段,推廣和擴展我們的完全託管的SaaS解決方案,使我們的客戶能夠有效和高效地自我管理他們的福利計劃。”洛克斯繼續說:“2023 年標誌着 20第四 NexGenrx 成立週年紀念日。這一重要的里程碑令我特別滿意,因爲公司繼續通過新的和創新的產品解決方案擴大其在市場的影響力。”

About NexgenRx
NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software as a Service) Model.

關於 NexgenRX
NexgenRx是加拿大唯一一家提供全方位服務的獨立第三方管理員和技術解決方案提供商,提供專有的完整前端、資格、註冊、小時庫和移動訪問功能,以及最先進的索賠裁決和全面的提供商網絡覆蓋。這些綜合功能使NexgenRX能夠以具有成本效益的SaaS(軟件即服務)模式提供計劃發起人、複雜的管理和健康福利技術應用程序。

NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at .

NexgenRx致力於與希望超越客戶和計劃成員期望並以具有競爭力的成本提供卓越的管理和索賠處理解決方案的組織建立合作伙伴關係。有關 NexgenRX 的更多信息,請訪問。

Caution Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The Company cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

關於前瞻性陳述的注意事項
除歷史事實陳述外,本新聞稿包含適用證券法所指的某些 “前瞻性信息”。前瞻性信息通常以 “計劃”、“期望”、“項目”、“打算”、“相信”、“預期”、“估計” 等詞語爲特徵,或者說某些事件或條件 “可能” 或 “將” 發生。儘管管理層認爲前瞻性信息中反映的預期是合理的,但無法保證這種預期會被證明是正確的。公司不能保證未來的業績、業績或成就。因此,無法表明取得的實際結果將全部或部分與前瞻性信息中列出的結果相同。

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether the Company's strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company's proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in the Company's annual Management's Discussion and Analysis, as filed under the Company's profile on SEDAR at . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

前瞻性信息基於管理層在陳述發表之日的意見和估計,受各種風險和不確定性以及其他因素的影響,這些因素可能導致實際事件或結果與前瞻性信息中的預期存在重大差異。可能導致業績與前瞻性信息中表達的結果存在重大差異的一些風險和其他因素包括但不限於:公司戰略和業務計劃能否產生預期收益的不確定性;資本的可用性和成本;識別和開發現有及新產品和技術並取得商業成功的能力;維持和提高產品和服務質量所需的支出水平;技術變化和法律的變化和法規;繼續開發和增強公司專有軟件技術;網絡安全風險以及公司在SEDAR上的簡介下提交的公司年度《管理層討論與分析》中披露的其他風險和不確定性 。提醒讀者,不應將這份風險因素清單解釋爲詳盡無遺。

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. The Company undertakes no duty to update any of the forward-looking information to conform such information to actual results or to changes in the Company's expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

本警示聲明明確限制了本新聞稿中包含的前瞻性信息。除非適用的證券立法另有要求,否則公司沒有義務更新任何前瞻性信息,以使此類信息與實際業績或公司預期的變化保持一致。提醒讀者不要過分依賴前瞻性信息。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對新聞稿的充分性或準確性承擔責任。

FOR FURTHER INFORMATION PLEASE CONTACT:
Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801

欲瞭解更多信息,請聯繫:
羅納德·C·洛克斯
NexGenrx Inc.
總裁兼首席執行官
416.695.3393 x801

Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393x803

加利福尼亞州凱利·埃勒註冊會計師
NexGenrx Inc.
首席財務官
416-695-3393x803

SOURCE: NexgenRx Inc.

來源: NexGenrx Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論